aTL (autologous tumour vaccine) for stage I-III renal cell carcinoma - horizon scanning review
NHSC
Record ID 32004000894
English
Authors' objectives:
This study aims to summarise the currently available evidence on aTL (autologous tumour vaccine) for stage I-III renal cell carcinoma.
Authors' recommendations:
aTL is a therapeutic autologous renal tumour cell vaccine that is pre-registration in the EU for patients with stage I-III renal cell carcinoma (RCC) and who have undergone radical nephrectomy. aTL was granted orphan drug status in October 2002. Results from a phase III trial show a statistically significant increase in 5-year progression free survival from 68% to 77% (NNT=10).
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2004
URL for published report:
http://www.psy-flow.com/sites/psy-flow/files/docs/flow.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Cancer Vaccines
- Kidney Neoplasms
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.